Lewis Moody's MND diagnosis highlights rugby's neurodegenerative disease risk

Lewis Moody, who captained England to victory in the 2003 Rugby World Cup, has been diagnosed with motor neurone disease. The announcement brings into sharp focus a troubling pattern emerging from medical research: elite rugby players face a risk of neurodegenerative disease that far exceeds what the general population experiences.

Motor neurone disease is a progressive condition in which signals from the brain and spine gradually fail to reach the muscles. The result is a slow deterioration—weakness that spreads, muscles that stiffen and waste, eventually affecting breathing, swallowing, and speech. There is no cure. The condition typically emerges in people over 50, and those diagnosed face a shortened lifespan. Early signs can be subtle: hands that grow stiff or weak, difficulty gripping objects, legs that fail on stairs. As the disease advances, people experience painful muscle twitches and cramps. Around half of those with MND develop changes in thinking and behavior. Neurologists diagnose it through blood tests, nerve tests, and MRI scans, though the variable speed at which symptoms progress can make diagnosis challenging.

In the general population, the lifetime risk of developing MND is roughly one in 300. At any given moment, about 5,000 adults in the UK are living with the condition. But for men who played international rugby, the numbers shift dramatically. A 2022 study from the University of Glasgow examined 412 former Scottish international rugby players and compared their health outcomes to more than 1,200 matched individuals from the broader population. The researchers found that former rugby internationals faced a 2.5 times greater risk of neurodegenerative disease overall—and a 15 times greater risk specifically of MND.

The study was led by consultant neuropathologist Prof Willie Stewart, who expressed genuine alarm at the findings. When the research was published, he stated that he was deeply concerned about what was unfolding in modern rugby, and worried that if the study were repeated in 20 years, the results would be even more troubling. He noted that while rugby has invested considerable effort in discussing and managing head injuries during training, the pace of actual progress has been slow. The implication was clear: the sport's current safeguards may not be sufficient to prevent the long-term neurological damage that appears to be accumulating in its players.

Moody is not alone. Doddie Weir, a former Scotland rugby union player, died from MND. Rob Burrow, who played rugby league for England, also died from the disease. Ed Slater, who played for Gloucester and Leicester Tigers, was diagnosed with MND in 2022. The pattern extends beyond rugby: Stephen Darby, a footballer who played for Liverpool and Bradford, was forced to retire at age 29 in 2018 after his own MND diagnosis. Research has shown that professional footballers, too, face elevated risk of neurodegenerative disease.

MND itself comes in several forms. Amyotrophic lateral sclerosis, or ALS, is the most common type, causing weakness and deterioration in the limbs, muscle rigidity, and cramping. People with ALS typically live two to five years after diagnosis. Bulbar onset MND affects the muscles of the face, throat, and tongue, with early symptoms including slurred speech and swallowing difficulties. Progressive muscular atrophy and primary lateral sclerosis are rarer variants.

Moody's diagnosis raises questions that extend beyond one athlete's health. It points to a gap between the conversation the sport has had about protecting its players and the actual protection those players receive. The research suggests that something about elite rugby—the repeated impacts, the accumulated head trauma, the physical demands—carries a cost that may not fully manifest until years or decades after a player's career ends. For Moody and others like him, that cost is now becoming visible.